EXONBIO

Executive Summary

ExonBio is a San Francisco-based private biotechnology company founded in 2020, specializing in antibody discovery and development for oncology, infectious disease, and vaccines. Its core asset is the proprietary Single Plasma cell INterrogation (SPIN®) platform, designed to generate high-affinity monoclonal antibodies with high efficiency. While the company has not disclosed total funding or valuation, its focus on a rapid antibody discovery platform positions it well in the competitive biotech landscape. The SPIN platform could enable faster identification of therapeutic candidates, addressing unmet needs in immuno-oncology and emerging infectious threats. As a private entity, ExonBio's progress is less transparent, but its technology could attract partnership interest from larger pharma seeking novel antibodies. The company's early stage and lack of disclosed pipeline data suggest significant risk, but the platform's potential to accelerate antibody development warrants attention. Key challenges include demonstrating platform superiority in preclinical studies and securing financing for pipeline advancement.

Upcoming Catalysts (preview)

• Q4 2026Announcement of strategic partnership or licensing deal for SPIN platform30% success
• Q2 2027Preclinical proof-of-concept data for lead antibody candidate40% success
• Q3 2026Series A funding round closure50% success